The APAF1 Polyclonal Knockout HAP1 cells comprise a CRISPR/Cas9-edited polyclonal population of HAP1 cells with targeted disruption of the APAF1 gene. This heterogeneous pool of APAF1-disrupted cells serves as a robust loss-of-function model for investigating intrinsic apoptosis signaling. The polyclonal format mitigates clonal artifacts and is ideal for population-based assays requiring consistent APAF1 inactivation in a near-haploid background.
HAP1 is a near-haploid fibroblast-like cell line originating from the KBM-7 chronic myeloid leukemia isolate. Its near-haploid karyotype simplifies genetic manipulation and ensures that each cell typically harbors only one functional allele, enhancing the efficiency of CRISPR-mediated gene disruption. HAP1 cells maintain functional apoptotic machinery and endogenous p53 signaling, rendering them a suitable host for probing core apoptosis regulators such as APAF1 in a leukemic context.
APAF1 functions as the central scaffold of the apoptosome, a key initiator of the intrinsic apoptotic pathway. Upon pro-apoptotic stimuli, cytochrome c released from mitochondria binds APAF1, promoting its ATP/dATP-dependent oligomerization. This complex recruits and activates procaspase-9 through dimerization, which then cleaves executioner caspases, including caspase-3, caspase-6, and caspase-7, to orchestrate cellular demolition. APAF1 activation is governed by upstream signals from p53 and the Bcl-2 family; pro-survival members like Bcl-xL and Mcl-1 block cytochrome c release, while pro-apoptotic BH3-only proteins promote it. Additionally, SMAC/DIABLO enhances caspase activity by antagonizing XIAP, ensuring robust apoptosome-driven apoptosis. Thus, APAF1 acts as a convergence point for mitochondrial damage signals.
In HAP1 cells, APAF1 disruption creates a defined model to study mitochondrial apoptosis without interference from redundant paralogs. This is particularly relevant in chronic myeloid leukemia, where BCR-ABL-driven survival signaling can suppress apoptotic pathways. By eliminating APAF1 function, researchers can delineate the mitochondrial contribution to drug-induced cell death, such as that triggered by DNA-damaging chemotherapeutics or targeted agents. The near-haploid genome further reduces complexity, offering a clear phenotype for APAF1-dependent apoptosis.
This knockout pool is suitable for diverse apoptosis assays. Western blotting can track cytochrome c translocation and caspase processing, confirming apoptosome activity. Caspase activity assays using fluorogenic substrates provide quantitative readouts. Annexin V/PI flow cytometry enables accurate apoptosis quantification. Co-immunoprecipitation can examine APAF1 complex formation with procaspase-9 and cytochrome c. Furthermore, this model is valuable for drug sensitivity profiling to assess chemoresistance mechanisms and for functional genomics screens identifying novel apoptosis modulators. For further information on cell culture, validation, and technical support, please contact Ascent Research.
